Table 3 Pap class distribution of included patients of which test results of all 3 assays are available (n = 11,333).
Pap class | Bethesda classification | Included samples (N) | Pap class distribution of tested cohort (DuSC) | Pap class distribution of Dutch screening populationa | HC2 hrHPV prevalence %(N) | cobas hrHPV prevalence %(N) | Aptima hrHPV prevalence %(N) | Overall hrHPV prevalence |
|---|---|---|---|---|---|---|---|---|
0 | - | 191 | 1.7% | 1.7% | 6.8% (13) | 5.2% (10) | 4.2% (8) | 5.4 ± 1.3% |
1 | Normal | 10,639 | 93.9% | 93.6% | 5.8% (620) | 5.7% (609) | 5.1% (545) | 5.5 ± 0.4% |
2 | ASC-US | 314 | 2.8% | 3.0% | 47.8% (150) | 41.1% (129) | 39.5% (124) | 42.8 ± 4.4% |
3a1 | LSIL | 71 | 0.6% | 0.7% | 91.5% (65) | 85.9% (61) | 84.5% (60) | 87.3 ± 3.7% |
3a2 | HSIL (moderate) | 50 | 0.4% | 0.4% | 94.0% (47) | 94.0% (47) | 94.0% (47) | 94.0 ± 0.0% |
3b | HSIL (severe) | 62 | 0.5% | 0.6% | 95.2% (59) | 93.5% (58) | 96.8% (60) | 95.2% ± 1.7% |
4 | CIS/AIS | 6 | 0.01% | 0.0% | 83.3% (5) | 83.3% (5) | 83.3% (5) | 83.3 ± 0.0% |
Total (N) | 11,333 | 959 | 919 | 849 |